Alphabet Earnings Surge on AI Growth, Cloud Revenue, and Strong Search Performance 
Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List 
Coles Group Q3 Sales Rise Driven by Supermarkets and E-Commerce Growth 
NAB First-Half Earnings Miss Forecasts Amid Rising Global Risks 
TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift 
Qualcomm Stock Surges Despite Weak Guidance After Q2 2026 Earnings Beat 
Seagate Stock Surges After Strong Q3 Earnings Beat and Bullish Outlook 
Amazon Stock Dips Despite Record Earnings as AI Infrastructure Spending Surges 
United Airlines Flight Hits Light Pole During Newark Landing, FAA Investigates 
Apple Q2 2026 Earnings Surge as iPhone 17 Sales Drive Record Revenue 
Middle East Conflict Impacts Australia and New Zealand Businesses 
Berkshire Hathaway Q1 Earnings Jump 18% as Greg Abel Signals Disciplined Growth Strategy 
Standard Chartered Q1 Profit Hits Record on Wealth and Investment Banking Growth 
Ford Q1 Earnings Beat Expectations, Stock Surges on Strong Guidance 
Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours 
Samsung Appoints New TV Business Head Amid Rising Competition from Chinese Rivals 
CAMBRIDGE, Mass., May 04, 2018 -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing neoantigen cancer vaccines, today announced that it will host a conference call and live audio webcast on Thursday, May 10, 2018 at 9:00 a.m. ET to discuss financial results for the first quarter of 2018. Genocea management will also provide an update on the Company's recent progress and upcoming milestones.
Interested participants may access the conference call by dialing (844) 826-0619 (domestic) or (315) 625-6883 (international) and refer to conference ID number 3866939. To join the live webcast, please visit the investor relations section of the Genocea website at http://ir.genocea.com.
A webcast replay will be available on the Genocea website beginning approximately two hours after the event, and will be archived for 30 days.
About Genocea Biosciences, Inc.
Genocea's mission is to help conquer cancer by designing and delivering targeted vaccines and immunotherapies. While traditional immunotherapy discovery methods have largely used predictive methods to propose T cell targets, or antigens, Genocea has developed ATLAS™, its proprietary technology platform, to identify clinically relevant antigens of T cells based on actual human immune responses. Genocea is using ATLAS in immuno-oncology applications to develop neoantigen cancer vaccines, while also exploring partnership opportunities for general cancer vaccines and a vaccine targeting cancers caused by Epstein-Barr Virus. Genocea expects to begin clinical development of its first neoantigen cancer vaccine, GEN-009, in 2018. For more information, please visit www.genocea.com.
Contact:
Jennifer LaVin
617-715-6687
[email protected]
